Summary of findings for the main comparison. Methotrexate compared to placebo for induction of remission in ulcerative colitis.
| Methotrexate compared to Placebo for induction of remission in ulcerative colitis | ||||||
| Patient or population: patients with induction of remission in ulcerative colitis Settings: Outpatient Intervention: Methotrexate Comparison: Placebo | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Placebo | Methotrexate | |||||
| Remission and complete withdrawal from steroids Follow‐up: mean 36 weeks | 486 per 10001 | 467 per 1000 (282 to 774) | RR 0.96 (0.58 to 1.59) | 67 (1 study) | ⊕⊕⊝⊝ low2 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Control group risk comes from control arm of study 2 Very sparse data (32 events)